HLS Therapeutics Inc.
HLS Therapeutics Inc., a prominent player in the pharmaceutical industry, is headquartered in Canada and operates extensively across North America. Founded in 2017, the company has quickly established itself as a leader in the development and commercialisation of innovative therapies, particularly in the areas of cardiovascular and central nervous system disorders. HLS Therapeutics is renowned for its unique portfolio of products, including the well-regarded drug, Nabilone, which addresses chronic pain and nausea. The company’s commitment to enhancing patient outcomes through specialised treatments has positioned it favourably within the competitive landscape. With a focus on delivering high-quality, evidence-based solutions, HLS Therapeutics continues to achieve significant milestones, solidifying its reputation as a trusted name in healthcare.
DitchCarbon Score
How does HLS Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
HLS Therapeutics Inc.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
HLS Therapeutics Inc.'s reported carbon emissions
HLS Therapeutics Inc., headquartered in Canada, currently does not report any carbon emissions data, as indicated by the absence of specific figures for emissions in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. As a result, HLS Therapeutics Inc. has not established any significant climate commitments or initiatives aimed at reducing its carbon footprint. The lack of emissions data and reduction strategies suggests that the company may still be in the early stages of developing a comprehensive climate action plan. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction, often setting Science-Based Targets (SBTi) to align with global climate goals. However, without specific commitments or data, HLS Therapeutics Inc. remains unaligned with these industry trends at this time.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
HLS Therapeutics Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
